Logo

PBYI

Puma Biotechnology, Inc.

PBYI

Puma Biotechnology, Inc. • NASDAQ
$5.04 ▼ -0.20% (-0.01)
Market Cap $253.97 M
52w High $6.12
52w Low $2.58
Dividend Yield 0%
P/E 6.81
Volume 153.75K
Outstanding Shares 50.39M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $54.475M ▲ $32.729M ▼ $8.844M ▲ 16.235% ▲ $0.18 ▲ $13.454M ▲
Q2-2025 $52.436M ▲ $33.499M ▲ $5.855M ▲ 11.166% ▲ $0.12 ▲ $10.765M ▲
Q1-2025 $46.007M ▼ $31.467M ▼ $2.974M ▼ 6.464% ▼ $0.06 ▼ $8.24M ▼
Q4-2024 $59.077M ▼ $31.791M ▲ $19.305M ▼ 32.678% ▲ $0.39 ▼ $17.7M ▼
Q3-2024 $80.542M $29.366M $20.317M 25.225% $0.41 $26.586M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $94.388M ▼ $202.862M ▲ $87.594M ▼ $115.268M ▲
Q2-2025 $96.024M ▲ $194.916M ▼ $90.198M ▼ $104.718M ▲
Q1-2025 $93.167M ▼ $196.181M ▼ $99.073M ▼ $97.108M ▲
Q4-2024 $100.965M ▲ $213.333M ▼ $121.208M ▼ $92.125M ▲
Q3-2024 $96.725M $220.721M $149.633M $71.088M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $8.844M ▲ $9.689M ▼ $506K ▲ $-11.332M ▼ $-1.137M ▲ $9.663M ▼
Q2-2025 $5.855M ▲ $14.082M ▲ $-11.248M ▼ $-11.202M ▲ $-8.368M ▼ $14.062M ▲
Q1-2025 $2.974M ▼ $3.612M ▼ $1.531M ▲ $-11.332M ▼ $-6.189M ▼ $3.551M ▼
Q4-2024 $19.305M ▼ $15.607M ▲ $-2.32M ▼ $-11.331M ▼ $1.956M ▲ $15.591M ▲
Q3-2024 $20.317M $11.038M $259K $-11.183M $114K $11.018M

Revenue by Products

Product Q4-2024Q1-2025Q2-2025Q3-2025
Product
Product
 $90.00M ▲$40.00M ▼$50.00M ▲$50.00M ▲
Royalty
Royalty
 $10.00M ▲$0 ▼$0 ▲$0 ▲

Five-Year Company Overview

Income Statement

Income Statement Puma’s income statement shows a company that has slowly moved from sizable losses to modest, consistent profitability. Sales have been fairly flat over the past several years, which suggests the current product base is mature rather than rapidly growing. However, the company has steadily tightened its costs, turning operating losses into small operating profits and lifting net income into positive territory. Profit margins have improved from clearly loss-making to modestly profitable, but the business is still small in scale and vulnerable to any setback in revenue or rising expenses. Overall, the trend is encouraging but not yet robust.

Balance Sheet

Balance Sheet The balance sheet has strengthened meaningfully from a few years ago. Equity has shifted from negative to clearly positive, reflecting the move to profitability and balance sheet repair. Debt has been worked down from earlier levels, which reduces financial strain, but it still represents a meaningful obligation for a company of this size. Cash balances are reasonable relative to the scale of the business, though not large enough to be considered a deep safety cushion by big‑pharma standards. In short, Puma looks more stable and solvent than in the past, but it remains a smaller, capital-constrained biotech rather than a cash-rich giant.

Cash Flow

Cash Flow Cash flow has improved from a mixed and sometimes negative pattern to consistently positive operating cash generation in recent years. The company is now producing cash from its core activities, and after only modest capital spending needs, free cash flow has turned positive as well. Capital expenditures are very light, which is typical for a company focused on drug development and commercialization rather than heavy manufacturing. This means more of each dollar of cash from operations is available to fund R&D, service debt, or build a cash buffer. The flip side is that the absolute level of cash flow is still modest, so any clinical or commercial disappointment could quickly pressure liquidity.

Competitive Edge

Competitive Edge Puma occupies a focused niche in oncology rather than competing broadly across cancer types. Its main product, NERLYNX, has carved out a specific role in HER2‑positive breast cancer, especially as extended adjuvant therapy and in heavily pre-treated metastatic patients. This gives Puma a defined, defensible slice of a much larger, very competitive market dominated by big pharma. The company’s strategy of in‑licensing de‑risked assets lets it punch above its weight in innovation, but also means it depends heavily on a small number of partnerships and products. The moat is real but narrow: a specialized, differentiated product position in HER2 disease and the potential for a novel pipeline drug, set against strong competitors, pricing pressure, and the long‑term risk of generic or newer branded rivals.

Innovation and R&D

Innovation and R&D Innovation is where Puma aims to stand out. NERLYNX offers a distinctive mechanism as an irreversible, pan‑HER inhibitor and is already validated through approval and commercial use. The next key growth driver is alisertib, an Aurora Kinase A inhibitor targeting small cell lung cancer and certain breast cancers, with orphan drug status underscoring its potential in an area of high unmet need. Puma’s R&D model is “asset‑light”: instead of discovering many drugs from scratch, it in‑licenses promising candidates and focuses on development, biomarker‑guided trials, and regulatory execution. This can be efficient but also concentrates risk in a small pipeline. Success of a few lead assets could transform the company; failure would leave a noticeable innovation gap.

Summary

Puma Biotechnology has evolved from a loss‑making, balance‑sheet‑strained biotech into a small but profitable oncology company with a healthier financial foundation. Revenue is steady rather than fast‑growing, with financial progress driven mainly by better cost control and operating discipline. The balance sheet and cash flows are much improved, though still modest in scale, leaving limited room for major missteps. Competitively, Puma’s strength is its narrow but differentiated position in HER2‑positive breast cancer and its strategy of in‑licensing de‑risked oncology assets. The company’s future hinges disproportionately on the continued performance of NERLYNX and the clinical success of alisertib. That creates both meaningful upside potential and concentrated risk, typical of a focused, mid‑stage biotechnology story rather than a diversified pharmaceutical platform.

NEWS

November 7, 2025 · 5:05 PM UTC

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Read more

November 6, 2025 · 4:05 PM UTC

Puma Biotechnology Reports Third Quarter 2025 Financial Results

Read more

October 23, 2025 · 4:10 PM UTC

Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results

Read more

October 2, 2025 · 5:21 PM UTC

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Read more